Cargando…
Outcome Comparison between Low-Dose Rabbit Anti-Thymocyte Globulin and Basiliximab in Low-Risk Living Donor Kidney Transplantation
The objective of this study was to compare outcomes between basiliximab and low-dose r-ATG in living donor kidney transplantation recipients with low immunological risk. Patients in the low-dose r-ATG group received 1.5 mg/kg of r-ATG for 3 days (total 4.5 mg/kg). Graft survival, patient survival, a...
Autores principales: | Kim, Sang Jin, Rhu, Jinsoo, Yoo, Heejin, Kim, Kyunga, Lee, Kyo Won, Park, Jae Berm |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7290680/ https://www.ncbi.nlm.nih.gov/pubmed/32370265 http://dx.doi.org/10.3390/jcm9051320 |
Ejemplares similares
-
Very Low Dose Anti-Thymocyte Globulins Versus Basiliximab in Non-Immunized Kidney Transplant Recipients
por: Masset, Christophe, et al.
Publicado: (2023) -
Development of a novel linear model for predicting recipient’s post-transplant serum creatinine level after living donor kidney transplantation: A multicenter cross-validation study
por: Rhu, Jinsoo, et al.
Publicado: (2019) -
Comparison of Basiliximab and Anti‐Thymocyte Globulin as Induction Therapy in Pediatric Heart Transplantation: A Survival Analysis
por: Ansari, David, et al.
Publicado: (2015) -
Antithymocyte globulin versus basiliximab induction for kidney transplantation in elderly patients: matched analysis within the Korean multicentric registry
por: Lee, Jun Young, et al.
Publicado: (2022) -
The comparative efficacy and safety of basiliximab and antithymocyte globulin in deceased donor kidney transplantation: a multicenter cohort study
por: Hong, Su Yeon, et al.
Publicado: (2023)